Prophylactic heparin therapy in acute promyelocytic leukemia

Cancer. 1978 Jun;41(6):2484-90. doi: 10.1002/1097-0142(197806)41:6<2484::aid-cncr2820410659>3.0.co;2-#.

Abstract

Twenty-four patients with acute promyelocytic leukemia were reviewed. Group I, treated between July 1970 and September 1973, received arabinosylcytosine and 6-thioguanine, and there was one complete remission, with 4/7 dying during induction with intracerebral hemorrhages, and 2/7 dying within one month. Group II, treated between May 1974 and March 1975, received daunomycin and arabinosylcytosine without heparin and 2/8 went into remission, with 6/8 dying during induction, 5 with intracerebral hemorrhages. Group III, treated between March 1975 and November 1976, received the identical chemotherapy as group II but with the addition of prophylactic heparin and there were 7/9 complete remissions, with 2/9 dying with intracerebral hemorrhages. In Group III there was an increased incidence of remission induction when compared to Group II (p less than .05) or when compared to Groups I and II combined (p less than .05). There was also a decreased incidence of fatal hemorrhage in Group III. This suggests that prophylactic heparin is useful during remission induction in acute promyelocytic leukemia.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antineoplastic Agents / therapeutic use*
  • Cerebral Hemorrhage / complications
  • Cerebral Hemorrhage / prevention & control
  • Disseminated Intravascular Coagulation / complications
  • Disseminated Intravascular Coagulation / prevention & control*
  • Drug Therapy, Combination
  • Female
  • Heparin / therapeutic use*
  • Humans
  • Leukemia, Myeloid, Acute / complications
  • Leukemia, Myeloid, Acute / drug therapy*
  • Male
  • Middle Aged
  • Remission, Spontaneous
  • Time Factors

Substances

  • Antineoplastic Agents
  • Heparin